Late-in-Review Advisory Panels: What Previous Cases Tell Us About Donanemab’s Prospects

Lilly’s Alzheimer’s candidate joins a club that no sponsor wants to be in, but one in which some members do get approved, albeit with less-than-ideal labeling.